Claims for Patent: 9,549,909

Summary for Patent: 9,549,909

Title:	Method for the treatment of dravet syndrome
Abstract:	A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Inventor(s):	Ceulemens; Berten (Leuven, BE), Lagae; Lieven (Edegem, BE)
Assignee:	The Katholieke Universiteit Leuven (Leuven, BE) University Hospital Antwerp (Edegem, BE)
Application Number:	13/887,014
Patent Claims:	1. A method of ameliorating seizures in a patient diagnosed with Dravet syndrome, comprising: orally administering an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof; orally administering an effective dose of stiripentol or a pharmaceutically acceptable salt thereof to said patient; orally administering an effective dose of valproate or a pharmaceutically acceptable salt thereof to said patient; and orally administering an effective dose of clobazam or a pharmaceutically acceptable salt thereof to said patient, whereby seizures are ameliorated in the patient. 2. The method of claim 1, wherein the fenfluramine or pharmaceutically acceptable salt thereof is administered in a dose of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient. 3. A method of ameliorating seizures in a patient diagnosed with Dravet syndrome, comprising: orally administering a liquid formulation comprised of an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof; orally administering an effective dose of stiripentol or a pharmaceutically acceptable salt thereof to said patient; orally administering an effective dose of valproate or a pharmaceutically acceptable salt thereof to said patient; and orally administering an effective dose of clobazam or a pharmaceutically acceptable salt thereof to said patient, wherein the fenfluramine or pharmaceutically acceptable salt thereof is administered in a dose of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient, whereby seizures are ameliorated in the patient.